The FDA has granted fast track designation to Faeth Therapeutics’ investigational combination PIKTOR plus paclitaxel for advanced or recurrent endometrial cancer.
What PIKTOR is
PIKTOR pairs two oral drugs, sapanisertib and serabelisib, designed to block multiple points along the PI3K/AKT/mTOR pathway — a signalling cascade altered in up to half of all solid tumours.
That prevalence explains why the pathway has attracted decades of drug development. It relays signals from growth factor receptors into the cell, controlling proliferation, survival and metabolism, and mutations activating it are among the most common alterations in cancer.
Why the pathway has been so difficult
Despite that prominence, drugs targeting it have consistently underdelivered, and the reason is feedback.
The pathway contains regulatory loops that normally prevent runaway signalling. Blocking one node releases those loops, and upstream components become more active in compensation — so inhibiting mTOR can increase signalling through PI3K and AKT, partially restoring the growth signal the drug was meant to remove.
Toxicity compounds the problem. The pathway is central to normal metabolism, particularly glucose handling, so inhibiting it causes hyperglycaemia and related effects that limit how much drug patients can tolerate — frequently below the level needed for sustained target suppression.
Blocking two points simultaneously is the logical response to the feedback problem: interrupting the compensating step as well as the primary one. Whether it can be done within a tolerable dose range is the practical question the pathway has always posed.
The chemotherapy resensitisation claim
According to the company, preclinical data suggest the approach can resensitise tumours to chemotherapy.
That is a different proposition from direct anti-tumour activity, and it explains the pairing with paclitaxel. PI3K/AKT/mTOR signalling promotes cell survival, and tumours with the pathway activated resist the cell death chemotherapy is trying to induce. Suppressing it should lower the threshold at which chemotherapy kills.
On that reading the combination is not two anti-cancer drugs added together but one drug making the other work — a mechanistically distinct claim requiring a comparison against chemotherapy alone to demonstrate.
Which patients
The designation covers patients with PI3K/AKT/mTOR pathway alterations whose disease has progressed after platinum-based chemotherapy and an immune checkpoint inhibitor.
That defines a population with genuinely limited options. Endometrial cancer treatment has improved substantially with immunotherapy, particularly for tumours with mismatch repair deficiency, but patients progressing after both chemotherapy and immunotherapy have little left.
Endometrial cancer is also a reasonable choice for this pathway specifically, since PI3K/AKT/mTOR alterations are unusually common in it — the biomarker-defined population is a large share of the disease rather than a sliver.
“Significant unmet need” remains for these patients, said Faeth CEO Anand Parikh.
What fast track actually provides
Fast track is a development designation, not an approval, and the combination remains investigational.
It offers more frequent interaction with the FDA during development, eligibility for accelerated approval and priority review if criteria are met, and the ability to submit an application in sections rather than all at once.
Those are procedural advantages that can shorten timelines. They say nothing about whether the drug works — the designation is granted on the basis of addressing a serious condition with unmet need, which describes the setting rather than the evidence.
Where the science stands
A Phase 2 study, FTH-PIK-201, is under way with topline results expected by the end of 2026. Faeth is also running a Phase 1b/2 in HR+/HER2- breast cancer, which dosed its first patient in April 2026, with interim results expected in 2027.
The breast cancer programme is a sensible extension, since PI3K pathway alterations are common there too and a PI3K inhibitor is already approved in that setting — establishing both that the target is valid and that tolerability is the constraint.
What the readout must show
Two things. That dual blockade produces meaningful tumour response where single-node inhibition has not, and that patients can tolerate both drugs together alongside chemotherapy at doses achieving that.
The metabolic angle in the company’s name
Faeth Therapeutics is named for a focus on cancer metabolism, and that framing connects to why this particular pathway is being targeted with a combination rather than a single agent.
The PI3K/AKT/mTOR cascade is not only a growth pathway — it is the cell’s principal system for coupling nutrient availability to growth decisions. mTOR in particular acts as a sensor integrating signals about amino acids, energy status and oxygen before permitting a cell to commit to dividing.
That dual role explains both the toxicity and an opportunity. Inhibiting the pathway disrupts normal glucose handling because the pathway is central to insulin signalling, which is why hyperglycaemia limits dosing. It also means tumour cells depending on the pathway are metabolically constrained in ways that might be exploitable through diet or other metabolic interventions alongside the drugs.
Companies pursuing that combination — pharmacological pathway inhibition plus metabolic manipulation — are attempting to widen a therapeutic window that has defeated drug-only approaches for two decades.
The second is where this class of combination has usually failed. Adding a second pathway inhibitor to solve a feedback problem also adds its toxicity to the first, and the history of this pathway is largely a history of combinations that worked mechanistically at doses patients could not sustain. Regulatory and R&D news, not medical advice.